testolactone (teslac) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Testolactone (Teslac brand name) is an anti-cancer agent, which was used as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer. The mechanism of testolactone action is reported to be related to the inhibition of aromatase enzymatic activity. Testolactone is no longer available in the USA.   NCATS

Chemistry

  • SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2
  • InChIKey: BPEWUONYVDABNZ-DZBHQSCQSA-N
  • Mol. Mass: 300.3921
  • ALogP: 3.59
  • ChEMBL Molecule:
    testolactone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Alternative names

1,2-didehydrotestololactone | 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone | 1-dehydrotestololactone | (4as,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2h-naphtho[2,1-f]chromene-2,8(4bh)-dione | delta(1)-testololactone | d-homo-17a-oxaandrosta-1,4-diene-3,17-dione | fludestrin | sq-9538 | teolit | teslac | testolacton | testolactona | testolactone | testolactonum | testolattone | δ1-testololactone

Organizations (3)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Breast Neoplasms (approved 1970)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Adrenal Gland Neoplasms (Phase 1)

Fibrous Dysplasia, Polyostotic (Phase 2)

Puberty, Precocious (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue